Hamilton, Waikato, New Zealand Clinical Trials

A listing of Hamilton, Waikato, New Zealand clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 46 clinical trials
Bronchiolitis in Infants Placebo Versus Epinephrine and Dexamethasone Study (BIPED)

We hypothesize that infants with bronchiolitis treated with inhaled epinephrine in the Emergency Department (ED) and a 2-day course of oral dexamethasone will have fewer hospitalizations over 7 days compared to infants treated with placebo. To examine this hypothesis, we will conduct a phase III, multicentre, randomized, double-blind trial. Infants …

Starship Children's Hospital
 (70.5 away) Contact site
  • 11 May, 2022
  • +10 other locations
Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)

Safety, immunogenicity and efficacy of GSK S. aureus candidate vaccine (GSK3878858A) when administered to healthy adults (dose-escalation) and to adults 18 to 64 years of age with a recent S. aureus skin and soft tissue infection (SSTI). In the dose-escalation safety lead-in phase in healthy adults safety and immunogenicity of …

Accepts healthy volunteers
bilateral ovariectomy
GSK Investigational Site
 (2.3 away) Contact site
  • 06 Jun, 2022
  • +25 other locations
Atrasentan in Patients With IgA Nephropathy (ALIGN)

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.

renal function
Middlemore Clinical Trials
 (60.5 away) Contact site
  • 17 Jun, 2022
  • +118 other locations
A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma (ITHACA)

Primary Objectives: Safety run-in: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM) Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when compared to …

bone marrow procedure
neutrophil count
Investigational Site Number :5540001
 (1.3 away) Contact site
  • 08 Jul, 2022
  • +103 other locations
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (CheckMate-67T)

The purpose of this study is to evaluate the drug levels, efficacy, safety, and tolerability of subcutaneous nivolumab versus intravenous nivolumab in participants with previously treated clear cell renal cell carcinoma that is advanced or has spread.

clear cell renal cell carcinoma
curative surgery
measurable disease
Local Institution - 0041
 (1.3 away) Contact site
  • 09 Jul, 2022
  • +56 other locations
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer

This study will evaluate the efficacy, safety, and pharmacokinetics of inavolisib in combination with palbociclib and fulvestrant compared with placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer whose disease progressed during treatment or within 12 months of completing adjuvant …

stage iv breast cancer
aromatase inhibitor
Auckland City Hospital; Clinical Oncology
 (67.7 away) Contact site
  • 10 Jul, 2022
  • +177 other locations
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations (RESOLUTE)

Phase 3 study to evaluate the efficacy and safety of a benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (≥300/μL). Eligible patients must have a history of ≥2 moderate and/or severe COPD exacerbations in the previous year …

eosinophil count
severe chronic obstructive pulmonary disease
Research Site
 (1.3 away) Contact site
  • 11 Jul, 2022
  • +290 other locations
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (GALAXI)

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease.

abdominal pain
fistulising crohn's disease
Auckland City Hospital
 (70.5 away) Contact site
  • 16 May, 2022
  • +440 other locations
Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma

This is a phase 3 study to compare the efficacy and safety of HBI-8000 or Placebo combined with nivolumab on patients with unresectable or metastatic melanoma and eligible patients who are not adolescents or patients with new, progressive brain metastasis will be stratified by PD-L1 expression and LDH level.

Tauranga Hospital
 (51.9 away) Contact site
  • 01 Jul, 2022
  • +41 other locations
A Study of Belcesiran in Patients With A1ATD-Associated Liver Disease (ESTRELLA)

This is a multiple dose, randomized, placebo-controlled, double-blind study of belcesiran to evaluate the safety, tolerability, PK, and PD in adult patients with PiZZ A1ATD-associated liver disease. The study will be conducted in 2 parallel cohorts. A total of up to 27 participants may be enrolled in a single cohort. …

alpha1-proteinase inhibitor (human)
Auckland Clinical Studies
 (69.7 away) Contact site
  • 12 Jul, 2022
  • +13 other locations